Search results for Tocilizumab

Tocilizumab Biosimilar – Anti-IL-6R mAb – Research Grade, ProteoGenix, PX-TA1030

Description of Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade General information on Tocilizumab Therapeutic Antibody The tocilizumab antibody is an IgG1 kappa monoclonal protein obtained from mouse hybridoma and subsequently humanized for use in antibody therapy. Tocilizumab acts as an immunosuppressant and it has been designed to bind the human interleukin 6 receptor (IL-6R), which occurs in membrane-bound or soluble form. The receptor is known to bind IL-6, a 21-26 kDa glycoprotein, and mediate proinflammatory reactions in response to infections or tissue injuries. IL-6 production is triggered locally and only during the early stages of inflammation. Despite its key role in the immune response, IL-6 overproduction has been observed in different chronic inflammatory diseases and some forms of cancer. Moreover, its presence has been linked with the excessive and potentially fatal inflammatory responses known as “cytokine storm.” Tocilizumab is one of the first humanized monoclonal antibodies ever to be licensed and commercialized as an efficient IL6R blocker. Due to its specificity, it is recurrently used to treat autoimmune conditions such as rheumatoid arthritis, cytokine release syndrome (or “cytokine storm”), and polyarticular juvenile idiopathic arthritis; some forms of cancer such as Castleman’s disease; and inflammatory diseases such as giant cell arteritis. Recent studies showed that IL-6 levels in COVID-19 patients on ventilators can be 10 times higher in comparison to patients with milder symptoms of the disease. Exacerbated levels of the proinflammatory molecule have previously been observed in other coronavirus-mediated diseases such as the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). In these diseases as in the case of COVID-19, the leading cause of death appears to be severe lung inflammation in the form of “cytokine storm.” The efficiency of Tocilizumab in the COVID-19 disease has been recently reported in several observational studies, including a study from Italy where researchers reported improved oxygenation in 74% and 65% of the patients on mechanical or non-invasive ventilation, respectively. Multiple randomized, double-blind, and placebo-controlled clinical trials are currently underway to validate the efficiency of this IgG1 antibody for the treatment of the COVID-19 disease. This product is for research use only.

Tocilizumab, Kyinno, KB-1168

Tocilizumab, Affinityimmuno, ab-131-tocilizumab

Tocilizumab, Abbexa, abx831572

Tocilizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL-6R, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis.

Tocilizumab Antibody, Abbexa, abx376591

Tocilizumab Antibody is a rabbit polyclonal antibody for the detection of Tocilizumab.

Tocilizumab ELISA Kit, ProteoGenix, KPTX164

Description of Tocilizumab ELISA Kit Tocilizumab ELISA Kit: A Comprehensive Guide Introduction Tocilizumab is a humanized monoclonal antibody that specifically targets the interleukin-6 (IL-6) receptor. It is used as a therapeutic agent for the treatment of various inflammatory diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. The Tocilizumab ELISA Kit is a highly sensitive and reliable tool for the detection and quantification of Tocilizumab in biological samples. In this article, we will provide a detailed description of the structure, activity, and application of this ELISA Kit. Structure of Tocilizumab Tocilizumab is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 148 kDa. The antibody is produced by recombinant DNA technology using Chinese hamster ovary (CHO) cells. It binds to the IL-6 receptor with high affinity, preventing IL-6 from binding to its receptor and inhibiting downstream signaling pathways. Activity of Tocilizumab Tocilizumab exerts its therapeutic effects by blocking the activity of IL-6, a pro-inflammatory cytokine that plays a key role in the pathogenesis of various inflammatory diseases. IL-6 is produced by a variety of cells, including immune cells, and is involved in the regulation of immune responses, hematopoiesis, and acute-phase reactions. Overproduction of IL-6 has been linked to the development of autoimmune disorders and chronic inflammatory conditions. By blocking the IL-6 receptor, Tocilizumab inhibits the downstream signaling pathways, leading to reduced inflammation and improved clinical outcomes. Application of Tocilizumab ELISA Kit The Tocilizumab ELISA Kit is a valuable tool for the detection and quantification of Tocilizumab in various biological samples, including serum, plasma, and cell culture supernatants. It is a highly sensitive and specific assay that utilizes the sandwich ELISA principle, where Tocilizumab is captured by a specific anti-Tocilizumab antibody coated on the microplate wells, and then detected by a second biotinylated anti-Tocilizumab antibody and streptavidin-HRP conjugate. The colorimetric signal is then measured and quantified using a microplate reader, with the intensity of the signal directly proportional to the amount of Tocilizumab present in the sample. The Tocilizumab ELISA Kit is widely used in clinical and research settings for the measurement of Tocilizumab levels in patient samples. It is an essential tool for monitoring Tocilizumab therapy and assessing treatment response in patients with inflammatory diseases. In addition, the kit can also be used for pharmacokinetic studies to determine the pharmacokinetic parameters of Tocilizumab, such as peak serum concentration and elimination half-life. Conclusion The Tocilizumab ELISA Kit is a valuable tool for the detection and quantification of Tocilizumab, a humanized monoclonal antibody used as a therapeutic agent for the treatment of inflammatory diseases. The kit provides a reliable and sensitive method for monitoring Tocilizumab therapy and assessing treatment response in patients. Its wide range of applications makes it an essential tool for both clinical and research settings. With its high specificity and sensitivity, the Tocilizumab ELISA Kit is a crucial asset in the field of immunology and drug development. Keywords: Tocilizumab, ELISA Kit, antibody, therapeutic target, IL-6 receptor, inflammatory diseases

Tocilizumab ELISA Kit, Abbexa, abx395053

Tocilizumab ELISA Kit is a quantitative ELISA kit for detection of Tocilizumab.Tocilizumab is a humanized IgG1 monoclonal antibody to the IL-6 receptor that is used largely as therapy of refractory rheumatoid arthritis and other inflammatory arthritides. Tocilizumab blocks the action of IL-6, which is a key proinflammatory cytokine that mediates a wide spectrum of biologic activities including activation of T cells, differentiation of B cells, induction of acute phase reactants, proliferation of fibroblasts, and damage to cartilage and joints. IL-6 levels are elevated in patients with active rheumatoid arthritis. In controlled trials and open label studies, tocilizumab therapy led to improvements in symptoms and laboratory abnormalities associated with several forms of inflammatory arthritis. Tocilizumab was approved for use in the United States in 2010 and current indications include rheumatoid arthritis, giant cell arteritis and both the polyarticular and systemic forms of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis). Tocilizumab is considered a disease modifying antirheumatic drug (DMARD) and improves signs and symptoms of disease and decreases cartilage and tissue destruction.

Anti-Tocilizumab Polyclonal Antibody, AntibodySystem, PAC36902

Tocilizumab Biosimilar - Research Grade, ichor.bio, ICH4012

Detects human IL-6 receptor. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tocilizumab.

Research Grade Tocilizumab (HY583026), abinScience, HY583026